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Obliterative bronchiolitis (OB) remains the most significant cause of death in long-term survival of lung transplantation. Using an
established murine heterotopic tracheal allograft model, the effects of different routes of administration of bone marrow-derived
multipotent stromal cells (MSCs) on the development of OB were evaluated. Tracheas from BALB/c mice were implanted into
the subcutaneous tissue of major histocompatibility complex- (MHC-) disparate C57BL/6 mice. At the time of transplant, bone
marrow-derived MSCs were administered either systemically or locally or via a combination of the two routes. The allografts were
explanted at various time points after transplantation and were evaluated for epithelial integrity, inflammatory cell infiltration,
fibrosis, and luminal obliteration. We found that the most effective route of bone marrow-derived MSC administration is the
combination of systemic and local delivery. Treatment of recipient mice with MSCs suppressed neutrophil, macrophage, and T-cell
infiltration and reduced fibrosis. These beneficial effects were observed despite lack of significant MSC epithelial engraftment or
new epithelial cell generation. Our study suggests that optimal combination of systemic and local delivery of MSCs may ameliorate
the development of obliterative airway disease through modulation of immune response.
1. Introduction
Lung transplantation is one of the few treatments available
for end-stage lung diseases such as chronic obstructive
pulmonary disease, idiopathic pulmonary fibrosis, cystic
fibrosis, alpha1-antitrypsin disease, and primary pulmonary
hypertension. Five-year survival rates for lung transplanta-
tion are significantly lower than other solid organ transplants
[1–4],andcomplicationsofchroniclungrejectionarerespon-
sible for the majority of deaths. Chronic lung rejection clini-
cally is termed bronchiolitis obliterans syndrome and patho-
logically classified as obliterative bronchiolitis (OB). During
disease development, chronic inflammatory and fibroprolif-
erative processes lead to small airway obstruction, for which
no effective treatment is currently available [5, 6]. OB was
initially thought to be caused by immune responses to donor
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antigens [7]; however, nonimmune mechanisms have also
b e e ns h o w nt op l a ya ni m p o r t a n tr o l ei nt h en a t u r a lh i s t o r y
of the disease [8–10]. Recent studies have emphasized on the
role of innate inflammatory cells such as polymorphonuclear
neutrophils (PMNs) and macrophages in chronic rejection
[5, 11] .P M N sa r ea m o n gt h efi r s ti n fl a m m a t o r yc e l l st o
be detected in the bronchoalveolar lavage and lung biopsy
specimens of patients with OB [12–14], and they are also
increased in the murine trachea transplant model [15, 16].
Macrophages also play an important role in the pathogenesis
of chronic rejection as depletion of macrophages ameliorates
OB [17]. In addition, a growing body of evidence supports
ac r i t i c a lr o l eo fl y m p h o c y t e si nt h ep a t h o g e n e s i so fO B
[5, 11].
Bone marrow-derived multipotent stromal cells (MSCs)
havebeenevaluatedexperimentallyandclinicallyinthetreat-
ment of a wide variety of pathological conditions. Though
originally harvested from bone marrow, MSCs have since
been isolated from multitude of sources, including adipose
tissue, placental tissue, dental pulp, and several others. The
paucity of MHC class I and the lack of MHC class II
and other costimulatory molecules allow administration of
these cells without significant host response [18]. Substantial
progress continues to be made with MSCs in lung injury and
repair [19, 20]. The ability to repair lung injury was initially
hypothesized to be due to the potential ability of MSCs to
acquire epithelial phenotype and engraft as structural lung
cells. However, engraftment with MSCs, as with most other
celltypesinvestigatedsofar,isarareeventofuncertainphys-
iological significance in lung. As such, emphasis has increas-
ingly shifted toward the profound immunomodulatory, anti-
inflammatory, and nonimmunogenic properties of MSCs. In
in vitro model systems, MSCs inhibit the proliferation and
function of a broad range of immune cells including T cells,
Bcells,NKcells,anddendriticcells.Notably,MSCsinhibitT-
cellproliferation,activation,andcytokinereleaseinresponse
toalloantigens[21].Inaddition,MSCsmayalsoaffectactions
of macrophages [22, 23]. In this context, a number of studies
reported the efficacy of MSC administration in various lung
injurymodelsin mice, for example, pulmonaryhypertension
[24],bronchopulmonarydysplasia[25],andOB[26].Current
study is aimed to evaluate different routes of MSC delivery
and their respective efficacy using an established heterotopic
airwaytransplantmousemodelofOB[27]. Our data indicate
that the most effective route of bone marrow-derived MSC
administration is the combination of systemic and local
delivery. Treatment of recipient mice with MSCs suppressed
inflammatory cell infiltration and reduced fibrosis without
significant epithelial engraftment.
2. Materials and Methods
2.1. Animal Maintenance and Heterotopic Airway Trans-
plant Model. C57BL/6 and BALB/c mice (6–12 weeks old)
were purchased from Charles River Laboratories (Wilming-
ton, MA). The 𝗽-Actin/enhanced green fluorescent protein
(eGFP) transgenic mice were originally established in Irving
Weissman’s lab [28]. The mice were housed in the Boston
Children’s Hospital animal facility under specific pathogen-
free conditions. An established model of OB involving het-
erotopic tracheal transplant with MHC-mismatched combi-
nations of C57BL/6 (H-2b) and BALB/c (H-2d) mice was
used as described previously [27]. Briefly, donor BALB/c
mice were euthanized and the trachea was resected and
immediately placed in ice-cold phosphate-buffered saline
(PBS). Recipient C57BL/6 mice were anesthetized and a
tracheal graft was inserted into the subcutaneous pocket on
thebackofthemouse.At2days,1week,2weeks,and4weeks
after transplantation, the recipient mice were euthanized
and the tracheas were harvested immediately. All animal
protocols were approved by the Children’s Hospital Animal
Care and Use Committee.
2.2. Bone Marrow-Derived MSC Isolation, Culture, and Dif-
ferentiation. Bonemarrow-derivedMSCswereisolatedfrom
the femurs and tibiae of 6- to 9-week-old C57BL/6 mice and
GFP mice as previously described [29]. Briefly, the ends of
each tibia and femur were clipped to expose the marrow
a n dt h e nt h eb o n e sw e r ei n s e r t e di n t oa d a p t e dc e n t r i f u g e
tubes. The tubes were centrifuged for 1 minute at 400g to
c o l l e c tt h em a r r o w .Th ep e l l e tw a sr e s u s p e n d e di n3m L𝗼-
minimum essential medium (MEM) medium (Invitrogen)
through a 21-gauge needle followed by filtration through a
70-𝜇m nylon mesh filter. The marrow cells were layered on
a Ficoll-Paque (Amersham, Piscataway, NJ) density gradient,
centrifuged, and plated. The cells were allowed to adhere to
the plastic surface of a 25cm
2 tissue culture flask (Falcon
3081) for 48h without disturbance in 𝗼-MEM medium
supplemented with 10% non-heat-inactivated FBS (Hyclone)
[30], 10% horse serum (Sigma), 1x L-Glutamine (Invitrogen),
and1%P/S,asdescribedbyPeisteretal.[29].Plasticadherent
cells were maintained in culture with media changed every
2-3 days. Following 2-3 passages, immunodepletion was
p e r f o r m e da sp e rp u b l i s h e dp r o t o c o l sa n dt h eI n t e r n a t i o n a l
Society for Cellular Therapy guidelines [31]. The cells were
negatively selected for FITC-CD11b, FITC-CD14, FITC-
CD19, PE-CD31, PE-CD34, and FITC-CD45, and positively
selected for APC-Sca-1 in a fluorescence-activated cell sorter
(MoFlo, Beckman-Coulter, Figures 1(a)–1(d)). Fluorescence-
conjugated antibodies were purchased from BD Biosciences,
BioLegend, and eBioscience. The differentiation potential of
MSCcultureswasassessedfollowingpublishedprotocols[29]
(Figures 1(e)–1(h)); Adipogenesis was induced by culturing
MSCs in complete 𝗼-MEM medium, supplemented with
5𝜇g/mL Insulin, 50𝜇MI n d o m e t h a c i n ,1 𝜇M Dexametha-
sone, and 0.5𝜇M 3-isobutyl-1 methylxanthine (IBMX). After
t h r e ew e e k s ,t h ec e l l sw e r efi x e dw i t h1 0 %F o r m a l i na n d
stained with 0.5% Oil Red O in Methanol (Figure 1(f)).
For chondrogenesis, StemXVivo mouse chondrogenic sup-
plement and base media (both from R&D Systems) were
used. Briefly, 2.5 × 10
5 MSCs were resuspended in 0.5mL
chondrogenic differentiation medium (base medium plus
chondrogenic supplement and penicillin/streptomycin) and
centrifuged to form a pellet in the medium. The MSC pellets
remainedintheculturewithfreshmediumevery3days.AfterStem Cells International 3
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Figure 1: Isolation and trilineage differentiation of mouse bone marrow MSCs. (a)–(d) Representative flow cytometry cell sorting plots
show sequential selection of cell populations as indicated by a red arrow: total adherent cells subjected to sorting (a), singlets (b), CD11b-,
CD14-, CD19-, CD31-, CD34-, and CD45-cells (c), and Sca-1+ cells (d). (e)–(h) Trilineage differentiation of mouse bone marrow MSCs:
Nondifferentiated MSCs in culture (e); black arrows indicate Oil Red O staining of lipid droplets within differentiated adipocytes (f); white
arrows indicate staining of Collagen type II (red) produced by differentiated chondrocytes (g); and empty arrows indicate Alizarin Red
staining of calcium deposit of differentiated osteocytes (h).
t h r e ew e e k s ,m e d i u mw a sc a r e f u l l ya s p i r a t e da n dt h eM S C -
pellets were fixed with 10% Formalin, embedded in paraffin,
and sectioned. Sheep antibody against type II Collagen and
anti-sheep IgG secondary antibody conjugated with North-
ernLights 557 (both from R&D Systems) were used to eval-
uate chondrogenesis of the mouse MSCs (Figure 1(g)). For
osteogenesis,cellsweresupplementedwith20mM𝗽-glycerol
phosphate, 50ng/mL thyroxine, 1nM Dexamethasone, and
0.5𝜇Mascorbate2-phosphatewithmediachangethreetimes
p e rw e e k .A tt h ee n do f3w e e k s ,t h ec e l l sw e r efi x e dw i t h1 0 %
Formalin and stained with Alizarin Red (Figure 1(h)). GFP-
MSCs were isolated from GFP mice, which were obtained
fromCarlaKim’slab(StemCellProgram,Children’sHospital
Boston).4 Stem Cells International
2.3. Administration of Bone Marrow-Derived MSCs. Bone
marrow-derived MSCs were delivered via different routes
prior to allograft transplant. For intratracheal injection (T),
1×1 0
5 MSCs in 20𝜇L PBS were injected into the lumen
of freshly isolated donor trachea, both ends of which were
then carefully tied up with a surgical suture. For intravenous
delivery, 1×1 0
5 MSCs in 100𝜇LP B Sw e r ei n j e c t e dv i a
retroorbital vein (IV). For the combination of these two
routes (IV + T) prior to tracheal transplant, 1×1 0
5 MSCs
were given bothintratracheallyand intravenously.Efficacy of
higher doses of MSCs, that is, 2×10
5 (2x) and 10×10
5 (10x),
was also examined in our allograft model. PBS was used as
control instead of MSCs in all experiments.
2.4. Preparation of Tracheal Explants. Recipient mice were
euthanized through asphyxiation and implanted tracheas
were removed immediately, weighed, and placed on ice.
A i r w a y sw e r efi x e di nf o r m a l i n - f r e ez i n cfi x a t i v e( B DB i o -
sciences Pharmingen, San Diego, CA), cut in half, and
paraffin-embedded with the cut side down. Cross-sections
of tracheal tissues (5𝜇m) were subjected to hematoxylin
and eosin (H&E) staining, Masson’s trichrome staining, or
various specific antibody staining as described below.
2.5. Assessment of Tracheal Luminal Obliteration and Epithe-
lial Integrity. H&E staining was performed on all tracheas
explanted at 2 days, 1 week, 2 weeks, and 4 weeks after
transplantation. Sections were then microscopically exam-
ined by two independent investigators who were blinded for
the experimental groups. A scale, from 0 (no obliteration)
to 4 (maximal obliteration), was used to grade luminal
obliteration. Epithelium of the tracheal sections was graded
by the percent coverage of the luminal surface.
2.6. Immunohistochemistry. Polymorphonuclear neutrophils
(PMNs) were stained with rat anti-mouse antibodies to gran-
ulocyte marker Ly-6C/6G (Gr-1). Macrophages were stained
with rat anti-mouse Mac-3 (BD Biosciences Pharmingen),
CD3-positivecellswithrabbitanti-mouseCD3(Abcam),and
GFP-positive cells with chicken anti-GFP (green fluorescent
protein) antibodies (Aves Labs), respectively. A standard
ABC vector kit (Vector Laboratories, Burlingame, CA) and
a DAB reagent were used. To visualize CD3-positive cells
a TSA Biotin System (Perkin Elmer) was used to enhance
staining. Specificity of the staining was confirmed by using
isotype control antibody. PMNs were counted manually in
t h ee n t i r es e c t i o n( o u t s i d ea n di n s i d eo ft h et r a c h e a ll u m e n )
of the allograft, CD3-positive cells, and macrophages were
counted in 4 random high-power fields under a microscope.
2.7. Assessment of Fibrosis and Analysis of Hydroxyproline
Content. We stained collagen on paraffin-embedded slides
to evaluate the extent of fibrosis by light microscopy using
a Masson’s trichrome staining kit (Sigma) according to the
manufacturer’s instruction. Tracheal hydroxyproline content
was measured to quantify collagen deposition using the
method outlined by Woessner Jr. [32]. Briefly, explanted
tracheas were manually homogenized in Hanks’ balanced
salt solution (HBSS) and dried in a speed-vac. Samples were
then hydrolyzed in 6M HCl for 18 hours at 110
∘C. Aliquots
(100𝜇L) were analyzed for hydroxyproline content by mix-
ing with chloramine-T and Ehrlich’s reagent to produce a
hydroxyproline chromophore that was quantified at 550nm
spectrophotometrically. Standard curve was generated for
each experiment in a 96-well plate using trans-4-Hydroxy-
L-proline (Sigma).
2.8. Statistical Analysis. The unpaired Student’s 𝑡-test was
used for statistical analysis. A 𝑃 value of less than 0.05 was
considered to indicate a significant difference between two
groups.
3. Results
3.1. MSCs Suppress Neutrophil Infiltration in the Allografts.
Histopathological changes in the initial phase of disease
development in OB show encroachment of neutrophils as a
response to inflammation [5]. To investigate the effects of
MSCs in our allograft model, cells stained with granulocyte-
antibody Ly6C/6G in the trachea tissue at 2 days, 1 week, 2
weeks, and 4 weeks after transplantation were counted. We
observed massive infiltration of neutrophils in the tracheal
parenchyma in PBS-control group, whereas the number of
neutrophilsintheMSC/IV+T-treatedmicewassignificantly
decreased in the 2-day and 1-week groups (Figure 2). This
inhibition was not significant in the later time points (2-
week groups: Control = 255, Experimental = 526, and 𝑃=
0.6;4 - w e e kg r o u p :C o n t r o l=3 4 ,E x p e r i m e n t a l=3 6 ,a n d
𝑃=0 . 9 ). Interestingly, no significant difference in the
numberofneutrophilswasfoundintheMSC/IV-orMSC/T-
treated mice at any time points (data not shown). These
data suggest that MSCs delivered via IV + T could suppress
neutrophil infiltration in the allografts during early stage of
inflammatory response.
3.2. MSCs Reduce Accumulation of Macrophages in the Allo-
grafts. Similar to our observations on neutrophils, accumu-
lationofMac3-positivelystainedmacrophagesinthetracheal
allograftwassignificantlyreducedintheMSC/IV+T-treated
mice at 1 week, 2 weeks, and 4 weeks after transplantation
(Figure 3). This beneficial reduction in macrophage accumu-
lation was delayed as macrophage numbers were comparable
in the MSC/IV + T-treated group and PBS-control group at 2
days after transplantation. Consistent to what we found with
the neutrophils, there was no significant difference noted in
the MSC/IV- or MSC/T-treated groups at any time points
(data not shown). These data suggest that MSCs delivered via
IV + T could reduce long-term accumulation of macrophage
in the allografts.
3.3. MSCs Inhibit T-Cell Response in the Allografts. T- and B-
lymphocytesareseenatthesiteofinjuryafterinnateimmune
cells have encroached into the allograft. Independent from
the route of delivery, significantly fewer CD3-positive T-
cells were seen in all MSC-treated groups, that is, IV, T, and
IV + T at 4 weeks after transplantation (Figure 4). At otherStem Cells International 5
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Figure 2: MSCs suppress neutrophil infiltration in the allografts. To assess neutrophil infiltration, donor tracheas from each treatment group
wereexplanted2days(PBS,𝑛=3 ;MSC,𝑛=3 )o r1week(PBS,𝑛=1 1 ;MSC,𝑛=8 )aftertransplantation.(a)Representativetrachealsections
stained with anti-Ly6C/6G antibodies (dark brown spots, 200x original magnification). (b) The total number of neutrophils per section was
counted, and the mean values of 2 days and 1 week after transplantation in the MSC/IV + T-treated group were compared to the respective
PBS control group. Significantly less neutrophils were found in the MSC/IV + T-treated group (
∗𝑃 < 0.05;
∗∗∗𝑃 < 0.001). All error bars in
(b) indicate SEM.
time points (2 days, 1 week, and 2 weeks), however, there
was no significant difference in the number of CD3 positive
cells between MSC-treatedand PBS-controlgroups(data not
s h o w n ) .Th e s ed a t as u g g e s tt h a tM S C sc o u l dr e d u c eT - c e l l
response in the allografts independent from the route of
delivery.
3.4. Less Fibrosis in MSC-Treated Recipients. During disease
course a repair response is initiated involving fibroblast pro-
liferation and extracellular matrix deposition [5]. To investi-
gate whether administration of MSC has beneficial effects on
thedevelopmentoffibrosis,hydroxyprolinecontentinMSC-
treated tracheas was analyzed. We found significantly lower
hydroxyproline concentrations at 4 weeks after transplanta-
tion in the IV + T group (Figure 5). There was no significant
difference in the IV + T group at 2 days, 1 week, and 2 weeks
after transplantation (data not shown). Once again, similar
to what we found with the neutrophils and macrophages, no
s i g n i fi c a n td i ff e r e n c ei nh y d r o x y p r o l i n ec o n t e n tw a ss e e ni n
the MSC/IV- or MSC/T-treated groups at any time points
(data not shown). These data suggest that MSCs delivered via
IV + T could prevent fibrosis in the allografts 4 weeks after
trachea transplantation.
3.5. MSCs Exert Allograft Protection in a Dose Independent
Manner. When MSCs were delivered through combination
of intratracheal (1×1 0
5 cells) and intravenous (1×1 0
5
cells) routes, two times the amount of MSCs were given
to the recipient mice. We designed experiments to rule
o u tt h ep o s s i b i l i t yt h a tt h eg r e a t e rb e n e fi c i a le ff e c to ft h e
MSC/IV + T-treatment was achieved because of the higher
dose of MSCs given. In the subsequent allograft transplan-
tations,2×10
5 MSCsand10×10
5 MSCswere injectedeither
intratracheally or intravenously. Comparison of Ly6C/6G-
positive cell (neutrophil) numbers showed no difference
between 1×1 0
5 MSC-treated and 2×1 0
5 cells or 10 × 10
5
MSC-treated mice (data not shown). These results indicated
thatMSCsexertedallograftprotectioninadoseindependent
manner.6 Stem Cells International
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Figure 3: MSCs reduce accumulation of macrophages in the allografts. To assess macrophage accumulation, grafts from each treatment
group were explanted at 1 week (PBS, 𝑛=5 ;M S C ,𝑛=4 ), 2 weeks (PBS, 𝑛=5 ;M S C ,𝑛=4 ), and 4 weeks (PBS, 𝑛=5 ;M S C ,𝑛=6 )a ft e r
transplantation. (a)–(c) Tracheal sections stained with anti-Mac3 antibodies (dark brown spots) showed reduced numbers of macrophages
in the MSC/IV + T-treated group at 1 week (a), 2 weeks (b), and 4 weeks (c) after transplantation when compared to the PBS-treated control
group (all representative images 200x original magnification). (d) Macrophages were counted in 4 random high power fields per section.
Mean counts of macrophages at 1 week, 2 weeks, and 4 weeks after transplantation in the MSC/IV + T-treated group were compared with
PBS-control group. Significantly fewer macrophages were seen in the MSC/IV + T-treated group at 1 week (
∗𝑃 < 0.02), 2 weeks (
#𝑃 < 0.02),
and 4 weeks (
򸀠򸀠𝑃 < 0.02). All error bars in (d) indicate SEM.Stem Cells International 7
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Figure 4: MSCs inhibit T-cell response in the allografts. To assess T-cell response, grafts from each treatment group were explanted 4 weeks
after transplantation; IV only (PBS, 𝑛=5 ;M S C ,𝑛=6 ), T (PBS, 𝑛=6 ;M S C ,𝑛=6 ), or IV + T group (PBS, 𝑛=4 ;M S C ,𝑛=5 ). (a)–(c)
Tracheal sections stained with anti-CD3 antibodies (dark brown spots) showed significantly less numbers of infiltrated CD3-positive cells in
the MSC/IV-treated group (a), MSC/T-treated group (b), and MSC/IV + T-treated group (c) at 4 weeks after transplantation when compared
tothePBS-controlgroup(allrepresentativeimages200xoriginalmagnification).(d)CD3-positivecellswerecountedin4randomhighpower
fieldspersection.Meancountsofcells4weeksaftertransplantationineachMSCtreatedgroup(IVonly,Tonly,IV+T)werecomparedtothe
respective PBS-control group. Significantly fewer CD3-positive cells were seen in all MSC-treated groups at 4 weeks in IV group (
∗𝑃 < 0.05),
Tg r o u p(
#𝑃 < 0.01), and IV + T group (
򸀠򸀠𝑃 < 0.05). All error bars in (d) indicate SEM.8 Stem Cells International
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Figure 5: Less fibrosis in MSC-treated recipients. Hydroxyproline-
basedquantificationofcollagenafter4weeksintrachealtransplants
from PBS-control (𝑛=6 ) and MSC/IV + T-treated (𝑛=6 )g r o u p .
MSC/IV + T-treated mice had significantly less collagen deposition
4weeksaftertransplantation(𝑃 = 0.01).AllerrorbarsindicateSEM.
3.6. Immunomodulation by MSCs Does Not Require Epithelial
Engraftment. We also performed tracheal allograft trans-
plantation experiments using GFP-labeled MSCs. We found
that MSCs given locally or systemically had no significant
integration in the tracheal epithelium (Figure 6). This result
suggested that epithelial engraftment may not be a prereq-
uisite for the immunomodulation by MSCs observed in this
study. Additionally the MSCs do not seem to contribute to
new epithelial cells in the tracheal allografts.
3.7. Lack of Improvement in Luminal Obliteration or Epithelial
Integrity. Development of OB is characterized by loss of
epithelium in the initial phase after transplantation and
subsequent fibroproliferative processes that lead to luminal
obliteration of the airways. We investigated whether MSCs
could prevent or slow down these processes. As shown in
Figure 7, the degree of luminal obliteration of tracheal allo-
grafts was comparable in all cases between MSC-treated and
PBS-control groups. Similarly, histopathologic evaluation of
luminal integrity of the trachea of MSC-treated recipients
didnotshowsignificantimprovementwhencomparedtothe
control group (data not shown). The lack of improvement
in luminal obliteration or epithelial integrity seems to be
consistent with the lack of MSC engraftment of the tracheal
allografts described above.
4. Discussion
Lung transplantation is the only available treatment option
formanyend-stage pulmonarydiseases. However, long-term
allograft survival in lung transplantation is hampered by
chronic graft dysfunction. Major improvements in surgical
techniques, management with immunosuppressive agents,
and control of infections have improved 1-yr survival to 70–
80%, but mortality due to OB remains alarmingly high, with
only 40–50% survival five years after OB develops [5, 9,
33, 34]. The lung has the highest rate of rejection among
all solid organ transplants, probably owing to epithelial
immunological vulnerability and injury due to its constant
exposure to airborne antigens, pathogens, and pollutants.
Although the pathophysiology leading to OB is not fully
understood, immune response against donor antigens plays
a key role in the disease development. Experiments using a
heterotopic tracheal transplantation model demonstrate that
alloimmunityisrequired[7].Currentlyavailabletherapeutics
have little efficacy. Consequently, OB remains a daunting
challenge with limited treatment options and unacceptably
high mortality. Thus, continued search for novel strategies to
reduce chronic graft dysfunction after lung transplantation is
warranted.
Cell-based regenerative therapies for lung diseases offer
great promise, including application of the widely studied
MSCs [20]. While it was initially thought that transplanted
MSCs would engraft and migrate to the sites of injury to
replace dysfunctional cells and interact with inflammatory
cells, accumulating evidence suggests that the majority of
systemically administered MSCs are trapped in capillary
networks, for example, the pulmonary first-pass effect, and
have a short life span, and distribution to other organs in
t h eb o d yi st r a n s i e n ta n dn e g l i g i b l e[ 35–38]. In the current
study, we investigated the effects of MSCs in a heterotopic
trachealtransplantationmodel.Ourfindingsshowthattreat-
ment of recipient mice with MSCs suppressed neutrophil,
macrophage, and T-cell infiltration and reduced fibrosis
s u p p o r t i n gt h ec r i t i c a lr o l eo fM S C si nl i m i t i n gt i s s u ei n j u r y
by modulating the immune responses. The observation that
the beneficial immunomodulatory effects of MSCs did not
require epithelial engraftment suggests paracrine effects of
thecells.Whenstimulatedbyinjuryandinflammation,MSCs
likely release a number of soluble factors which may exert
a net trophic effect on tissue, stimulate angiogenesis, limit
cellular apoptosis and recruit immune cells to the site of
injury,andultimatelyreducefibrosis.Eachoftheseeffectscan
occurindependentlyofMSCengraftmentanddifferentiation
[39].EarlierstudiesinvestigatedMSCsinheterotopictracheal
transplantation model [26, 40], but epithelial integration has
not been examined. Furthermore, the most effective method
of MSC administration is unknown and particularly impor-
tant when considering future clinical application. Our study
indicates that combination of local and systemic delivery
of MSCs more effectively ameliorates the development of
inflammation in obliterative airway disease, which suggests
t h a tl o c a la sw e l la ss y s t e m i ci m m u n o m o d u l a t i o ni si m p o r -
tant. In addition, our study show that the MSCs did not
engraft nor did they seem to contribute to new epithelial
cells. Since improved epithelial integrity prevents luminal
obliteration after tracheal injection of epithelial/progenitor
cells[41],lackofepithelialintegrationofMSCsmightexplain
the lack of improvement in luminal obliteration in our
experiments.
While clinical studies have just begun to examine the
effectiveness of MSCs in the prevention of solid organ allo-
graft rejection (ClinicalTrials.gov identifier NCT01668576:
Properties of Mesenchymal Stem Cells in Lung Transplant),
abundant evidence from animal models suggests that this
approach may have merit. In the majority of these investiga-
tions, allogeneic MSCs were coinfused at the time of organStem Cells International 9
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Figure6:ImmunomodulationbyMSCsdoesnotrequireepithelialengraftment.Immunohistochemicalstainingwasperformedtodetermine
epithelialengraftmentofGFP-MSCsintransplantedtrachea.(a)showspositiveGFP-stainingoftrachealepithelium(browncolorindicatedby
asolidarrow)andparenchymalcellsofatracheasectionfromGFP-mouse.(b)showsnegativeGFP-stainingoftrachealepithelium(indicated
by an empty arrow) from IV + T control group. (c) shows absence of GFP-MSCs on tracheal epithelium (indicated by an empty arrow) from
IV + T MSC-treated group.
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Figure 7: No significant changes in tracheal luminal obliteration. MSC/IV + T-treated group ((a) representative image 40x original
magnification) and PBS-control group were explanted 4 weeks after transplantation. Histological grading of H&E stained samples did not
showsignificantdifferencesinmedianobliterationwhencomparedtoPBS-controlgroups(b).Likewise,noMSC/IV-treatedgrouporMSC/T-
treated group showed any difference in luminal obliteration (data not shown).
transplantation.Improved allograft survival and reduction in
the need for concurrent pharmacological immunosuppres-
sionhavebeenreported[42–44].Notsurprisingly,thepotent
immunomodulatory effects of MSCs on T-cell response
appear to be of primary importance in their ability to prevent
allograft rejection. Interestingly, in the current study MSCs
exerted allograft protection in a dose independent manner,
the underlying mechanism of which warrants further inves-
tigation. Previous studies with genetic lineage tracing and
s e l e c t i v ea b l a t i o no fe p i t h e l i a lc e l l si n d i c a t et h ep r e s e n c eo f
lung progenitor cells [19, 20]. The difficulties to expand these
putative lung progenitors adequately post a major challenge
for their therapeutic application. A recent report suggests
that injection of recipient epithelial progenitors prevents10 Stem Cells International
epithelial loss and decreases OB development [41]. Thus, a
combination of MSCs and lung epithelial progenitors may
represent a rational proposition for future experimentation,
where epithelial progenitors preserve luminal integrity and
MSCs attenuate inflammation. A multipronged treatment
may be the best way to approach a complex problem of
rejection in the immunogenic milieu of the lung that is
constantly exposed to triggers of inflammation. A multitude
of desirable properties of MSCs may render these cells
useful as a therapeutic modality for variety of conditions
includinglungtransplantation.Furthereffortsonelucidating
the molecular mechanisms of MSCs’ beneficial effects will
help us understand the most effective ways to use these cells
clinically.
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